Posttreatment Lyme disease syndrome
- PMID: 25999226
- DOI: 10.1016/j.idc.2015.02.012
Posttreatment Lyme disease syndrome
Abstract
The prognosis following appropriate antibiotic treatment of early or late Lyme disease is favorable but can be complicated by persistent symptoms of unknown cause termed posttreatment Lyme disease syndrome (PTLDS), characterized by fatigue, musculoskeletal pain, and cognitive complaints that persist for 6 months or longer after completion of antibiotic therapy. Risk factors include delayed diagnosis, increased severity of symptoms, and presence of neurologic symptoms at time of initial treatment. Two-tier serologic testing is neither sensitive nor specific for diagnosis of PTLDS because of variability in convalescent serologic responses after treatment of early Lyme disease. Optimal treatment of PTLDS awaits more precise understanding of the pathophysiologic mechanisms involved in this illness and future treatment trials.
Keywords: Fatigue; Fibromyalgia; Musculoskeletal pain; Persistent symptoms; Posttreatment Lyme disease syndrome.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Update of the Swiss guidelines on post-treatment Lyme disease syndrome.Swiss Med Wkly. 2016 Dec 5;146:w14353. doi: 10.4414/smw.2016.14353. eCollection 2016. Swiss Med Wkly. 2016. PMID: 27922168 Review.
-
The challenge of Lyme disease: tired of the Lyme wars.Neth J Med. 2011 Mar;69(3):98-100. Neth J Med. 2011. PMID: 21444933 No abstract available.
-
Common misconceptions about Lyme disease.Am J Med. 2013 Mar;126(3):264.e1-7. doi: 10.1016/j.amjmed.2012.10.008. Epub 2013 Jan 12. Am J Med. 2013. PMID: 23321431 Review.
-
Persistent Symptoms After Treatment of Lyme Disease.Infect Dis Clin North Am. 2022 Sep;36(3):621-638. doi: 10.1016/j.idc.2022.04.004. Infect Dis Clin North Am. 2022. PMID: 36116839 Free PMC article. Review.
-
Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here?Qual Life Res. 2013 Feb;22(1):75-84. doi: 10.1007/s11136-012-0126-6. Qual Life Res. 2013. PMID: 22294245 Free PMC article.
Cited by
-
Identification of Major Histocompatibility Complex Class II Epitopes From Lyme Autoantigen Apolipoprotein B-100 and Borrelia burgdorferi Mcp4 in Murine Lyme Arthritis.J Infect Dis. 2024 Aug 14;230(Supplement_1):S27-S39. doi: 10.1093/infdis/jiae324. J Infect Dis. 2024. PMID: 39140726
-
Development and Application of an In Vitro Tick Feeding System to Identify Ixodes Tick Environment-Induced Genes of the Lyme Disease Agent, Borrelia burgdorferi.Pathogens. 2024 Jun 7;13(6):487. doi: 10.3390/pathogens13060487. Pathogens. 2024. PMID: 38921785 Free PMC article.
-
Fibroblast growth factor receptor inhibitors mitigate the neuropathogenicity of Borrelia burgdorferi or its remnants ex vivo.Front Immunol. 2024 Apr 4;15:1327416. doi: 10.3389/fimmu.2024.1327416. eCollection 2024. Front Immunol. 2024. PMID: 38638441 Free PMC article.
-
Prevalence of Powassan Virus Seropositivity Among People with History of Lyme Disease and Non-Lyme Community Controls in the Northeastern United States.Vector Borne Zoonotic Dis. 2024 Apr;24(4):226-236. doi: 10.1089/vbz.2022.0030. Epub 2024 Mar 1. Vector Borne Zoonotic Dis. 2024. PMID: 38436222
-
Dysautonomia following Lyme disease: a key component of post-treatment Lyme disease syndrome?Front Neurol. 2024 Feb 8;15:1344862. doi: 10.3389/fneur.2024.1344862. eCollection 2024. Front Neurol. 2024. PMID: 38390594 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
